Equities

Radiopharm Theranostics Ltd

Radiopharm Theranostics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.033
  • Today's Change0.00 / 0.00%
  • Shares traded106.12k
  • 1 Year change-73.12%
  • Beta--
Data delayed at least 20 minutes, as of May 31 2024 03:25 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Radiopharm Theranostics Limited is an Australia-based clinical-stage company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. It has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

  • Revenue in AUD (TTM)0.00
  • Net income in AUD-46.82m
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Althea Group Holdings Ltd28.70m-20.99m10.94m----0.7138--0.3813-0.059-0.0590.07960.03780.61812.475.53---45.22-31.09-66.73-36.3254.6450.76-73.15-101.390.4899-46.550.2756--22.43335.18-13.21------
TrivarX Ltd20.81k-3.74m11.06m4.00--1.09--531.50-0.0182-0.01820.000090.02490.0023-------42.02-41.56-47.15-50.51100.0092.74-17,949.78-334.16---147.210.0072---4.69-18.0675.85------
Firebrick Pharma Ltd0.00-4.57m11.72m----6.72-----0.0266-0.02660.000.00890.00-------120.70---136.04----------4.37--0.00---79.85---79.18------
Adalta Ltd3.56m-5.04m13.33m----5.43--3.74-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Tissue Repair Ltd457.52k-3.28m13.91m----0.8075--30.40-0.0542-0.05420.00760.28480.0209--7.95---14.96---15.46--98.19---716.30--25.84--0.00------38.95------
Patrys Ltd1.70m-5.12m14.40m15.00--2.87--8.50-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Radiopharm Theranostics Ltd0.00-46.82m14.73m----0.4907-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
BTC Health Ltd16.03k-8.26m14.91m1.00--2.759.03930.11-0.0305-0.03050.000050.01670.0017--0.031---89.67-23.15-91.36-24.64-----51,522.02-2,498.18---0.07870.00---86.04-26.76-1,665.01------
Medlab Clinical Ltd366.64k-3.94m15.07m14.00------41.11-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Chimeric Therapeutics Ltd0.00-11.31m15.42m----0.9425-----0.027-0.0270.000.01910.00-------45.96---69.36-------------10.010.1596-------60.40------
Oncosil Medical Ltd355.30k-11.71m16.66m2.00--2.56--46.89-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Argent BioPharma Ltd1.32m-17.02m16.75m----9.96--12.65-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Rhythm Biosciences Ltd157.67k-8.63m17.65m----12.90--111.95-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Auscann Group Holdings Ltd2.05m-9.44m17.76m27.00------8.67-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Lumos Diagnostics Holdings Ltd12.39m-13.30m17.81m----1.28--1.44-0.0357-0.03570.03520.02890.34182.246.37---36.70-40.15-55.14-56.6759.7345.97-107.38-162.900.479-6.250.4803---9.4239.2980.38---38.50--
Algorae Pharmaceuticals Ltd84.10k-2.25m18.56m----5.12--220.71-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Data as of May 31 2024. Currency figures normalised to Radiopharm Theranostics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.59%Per cent of shares held by top holders
HolderShares% Held
Cranport Pty Ltd.as of 27 Sep 20222.68m0.59%
Data from 10 Apr 2024 - 10 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.